ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,440.00
-200.00 (-4.31%)
At close: Apr 2, 2026
Market Cap180.81B -13.6%
Revenue (ttm)56.67B -6.0%
Net Income-10.68B
EPSn/a
Shares Out40.72M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume120,743
Average Volume119,098
Open4,670.00
Previous Close4,640.00
Day's Range4,425.00 - 4,740.00
52-Week Range4,425.00 - 6,350.00
Beta0.59
RSI34.71
Earnings Daten/a

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements